X4 Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XFOR research report →
Companywww.x4pharma.com
X4 Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
- CEO
- Adam R. Craig
- IPO
- 2017
- Employees
- 143
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $43.01M
- P/E
- -4.77
- P/S
- 4.77
- P/B
- 2.83
- EV/EBITDA
- 1.79
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 79.44%
- Op Margin
- -1084.38%
- Net Margin
- -1106.30%
- ROE
- -94.90%
- ROIC
- -39.53%
Growth & Income
- Revenue
- $35.11M · 1273.21%
- Net Income
- $-79,199,000 · -111.48%
- EPS
- $-1.87 · 66.55%
- Op Income
- $-86,883,000
- FCF YoY
- 35.89%
Performance & Tape
- 52W High
- $4.83
- 52W Low
- $1.35
- 50D MA
- $4.13
- 200D MA
- $3.65
- Beta
- 0.32
- Avg Volume
- 457.02K
Get TickerSpark's AI analysis on XFOR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | KIRSKE DAVID | sell | 16,961 |
| Jan 1, 26 | Bridger Gary | other | 110,000 |
| Jan 1, 26 | de Craecker Francoise | other | 110,000 |
| Jan 1, 26 | WYZGA MICHAEL S | other | 110,000 |
| Jan 1, 26 | Stewart Murray | other | 110,000 |
| Oct 29, 25 | Craig Adam R | other | 2,329,154 |
| Oct 29, 25 | Volpone John | other | 2,329,154 |
| Oct 29, 25 | KIRSKE DAVID | other | 1,552,769 |
| Oct 23, 25 | Craig Adam R | buy | 86,206 |
| Aug 12, 25 | Volpone John | other | 1,609,873 |
Our XFOR Coverage
We haven't published any research on XFOR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XFOR Report →